Previous 10 | Next 10 |
The following slide deck was published by Reata Pharmaceuticals, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Reata Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation
Reata Pharmaceuticals press release (NASDAQ:RETA): Q4 Non-GAAP EPS of -$1.59 beats by $0.34. Revenue of $0.93M (-70.9% Y/Y) misses by $0.83M. At December 31, 2021, the company cash and cash equivalents of $590.3 million, as compared to $818.2 million at December 31, 2020 The Company updated t...
Initiated Rolling Submission of NDA for Omaveloxolone for Treatment of Patients with Friedreich's Ataxia; Actively Preparing for Commercial Launch Updated Cash Guidance - Sufficient to Fund Operations Through End of 2024 Conference Call with Management on Feb...
Reata Pharmaceuticals (NASDAQ:RETA) has lost ~4% in the post-market Friday after the company announced that the U.S. Food and Drug Administration (“FDA”) issued a Complete Response Letter (CRL) regarding its New Drug Application (“NDA”) for bardoxolone me...
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), today announced that the U.S. Food and Drug Administration (“FDA”) has issued a Complete Response Letter (“CRL”) regarding the New Drug...
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on...
San Francisco, California--(Newsfile Corp. - February 17, 2022) - Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now . A securities fraud class action has been filed and certain investors may have valuable claim...
NEW YORK, NY / ACCESSWIRE / February 15, 2022 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz B...
Stanley Druckenmiller's Duquesne Family Office takes new positions in WillScot Mobile Mini Holdings (NASDAQ:WSC) with a 1.50M stake, Snap (NYSE:SNAP) with 1.44M shares, and Chevron with 824K shares, according to the firm's latest 13F. It exited Nektar Therapeutics (NASDAQ:NKTR), Farfetch (NYS...
San Francisco, California--(Newsfile Corp. - February 14, 2022) - Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now . A securities fraud class action has been filed and certain investors may have valuable claims. Cla...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...